Immune Regulation News Volume 13.44 | Nov 25 2021

    By
    Justin.choi
    -
    0
    107







    2021-11-16 | IRN 13.44


    Immune Regulation News by STEMCELL Technologies
    Vol.13.44 – 26 November, 2021
    TOP STORY

    NogoA-Expressing Astrocytes Limit Peripheral Macrophage Infiltration after Ischemic Brain Injury in Primates

    Utilizing single-nuclei transcriptomics to characterize astrocytes after ischemic stroke in the visual cortex of the marmoset monkey, researchers observed nearly complete segregation between stroke and control astrocyte clusters.
    [Nature Communications]

    Full Article
    Find the Right Antibodies for Your Stem Cell Research. Learn More
    PUBLICATIONSRanked by the impact factor of the journal

    ACC1-Expressing Pathogenic T Helper 2 Cell Populations Facilitate Lung and Skin Inflammation in Mice

    Scientists reported the high expression of acetyl-CoA carboxylase 1 in the pathogenic CD4+ T cell population in the lung and skin.
    [Journal of Experimental Medicine]

    Abstract

    DCIR and Its Ligand Asialo-Biantennary N-glycan Regulate DC Function and Osteoclastogenesis

    Researchers showed that Dcir−/− mice spontaneously developed autoimmune enthesitis and sialadenitis, and also developed metabolic bone abnormalities.
    [Journal of Experimental Medicine]

    AbstractPress Release

    PlexinA4 Mediates Cytotoxic T Cell Trafficking and Exclusion in Cancer

    The authors showed that expression of the axon guidance molecule PlexinA4 in cytotoxic T cell, especially in effector/memory CD8+ T cells, was induced upon T cell activation, sustained in the circulation, but reduced when entering the tumor bed.
    [Cancer Immunology Research]

    Abstract

    ILC3s Control Airway Inflammation by Limiting T Cell Responses to Allergens and Microbes

    Investigators demonstrated that lymphoid-tissue-inducer-like ILC3s were enriched in the lung-draining lymph nodes of healthy mice and humans.
    [Cell Reports]

    Full ArticleGraphical Abstract

    EZH2 Inhibition Compromises α4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8+ T Cells

    The authors explored the combination between enhancer of zeste homolog 2 (EZH2) inhibitor and an agonist antibody targeting the T cell costimulatory receptor 4-1BB.
    [Frontiers in Immunology]

    Full Article

    CD8+ T Cells Expressing an HLA-DR1 Chimeric Antigen Receptor Target Autoimmune CD4+ T Cells in an Antigen-Specific Manner and Inhibit the Development of Autoimmune Arthritis

    Through the engineering of an HLA-DR1 chimeric Ag receptor (CAR), researchers produced CD8+ CAR T cells that target CD4+ T cells in an Ag-specific manner and tested their ability to inhibit the development of autoimmune arthritis in a mouse model.
    [Journal of Immunology]

    Abstract

    cGMP Signaling Pathway That Modulates NF-κB Activation in Innate Immune Responses

    Scientists showed that Drosophila NF-κB signaling was activated via a pathway in parallel with the Toll- receptor by receptor-type guanylate cyclase, Gyc76C.
    [iScience]

    AbstractFull ArticleGraphical Abstract

    Investigators Modified the Classical Antigen-Induced Arthritis Model by Using Citrullinated Human Plasma Fibrinogen as an Immunogen to Investigate the Mechanism of Inflammation-Driven Joint Damage by Citrullinated hFIB in C57BL/6 Mice.

    The authors modified the classical antigen-induced arthritis model by using citrullinated human plasma fibrinogen as an immunogen to investigate the mechanism of inflammation-driven joint damage by citrullinated human plasma fibrinogen (hFIB) in C57BL/6 mice.
    [International Immunopharmacology]

    Abstract
    Use ImmunoCultâ„¢ to differentiate mouse CD4+ cells to Tregs.
    REVIEWS

    Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Limitations and Prospects: A Systematic Review

    Pancreatic ductal adenocarcinoma is not sensitive to monotherapy with immune checkpoint inhibitors, which might be related to the inhibitory immune microenvironment of pancreatic cancer.
    [Cell Communication and Signaling]

    Full Article
    INDUSTRY AND POLICY NEWS

    Todos Medical Announces Exclusive License & Distribution Agreement with T Cell Protect Hellas S.A. for Tollovid® Products Covering 30 Countries in Europe

    Todos Medical, Ltd. announced that it has entered into an exclusive European licensing & distribution agreement with T Cell Protect Hellas S.A. for a product based on its Tollovid® and Tollovid Daily™ 3CL protease inhibitor and immune support dietary supplements.
    [Todos Medical, Ltd.]

    Press Release

    Bristol Myers Squibb Receives European Commission Approval of Zeposia (Ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis

    Bristol Myers Squibb announced the European Commission has granted a Marketing Authorization for Zeposia for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
    [Bristol Myers Squibb]

    Press Release
    FEATURED EVENT

    ISSCR: Stem Cells and Regenerative Medicine

    January 12 – 14, 2022
    Shanghai, China

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Researcher – T Cell Immunity

    University Medical Center Freiburg – Freiburg, Germany

    PhD Positions – Cell Surface Glycome

    The University of British Columbia – Vancouver, British Columbia, Canada

    Postdoctoral Fellow – Bioinformatics

    University Medical Center Schleswig-Holstein – Kiel, Germany

    Research Scientist – Immunology

    AbCellera – Vancouver, British Columbia, Canada

    Scientist – Immune System-Tumor Interactions

    Oregon Health & Science University – Portland, Oregon, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Immune Regulation News Twitter